Rocket Pharmaceuticals (RCKT) Competitors $16.98 +0.33 (+1.98%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends RCKT vs. RCUS, AUPH, YMAB, HRTX, AMRN, CYTK, NUVL, BPMC, KRYS, and OGNShould you be buying Rocket Pharmaceuticals stock or one of its competitors? The main competitors of Rocket Pharmaceuticals include Arcus Biosciences (RCUS), Aurinia Pharmaceuticals (AUPH), Y-mAbs Therapeutics (YMAB), Heron Therapeutics (HRTX), Amarin (AMRN), Cytokinetics (CYTK), Nuvalent (NUVL), Blueprint Medicines (BPMC), Krystal Biotech (KRYS), and Organon & Co. (OGN). These companies are all part of the "medical" sector. Rocket Pharmaceuticals vs. Arcus Biosciences Aurinia Pharmaceuticals Y-mAbs Therapeutics Heron Therapeutics Amarin Cytokinetics Nuvalent Blueprint Medicines Krystal Biotech Organon & Co. Rocket Pharmaceuticals (NASDAQ:RCKT) and Arcus Biosciences (NYSE:RCUS) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, dividends, institutional ownership, earnings, media sentiment, valuation, community ranking and profitability. Do analysts prefer RCKT or RCUS? Rocket Pharmaceuticals presently has a consensus price target of $51.75, suggesting a potential upside of 204.77%. Arcus Biosciences has a consensus price target of $33.67, suggesting a potential upside of 117.20%. Given Rocket Pharmaceuticals' higher possible upside, equities research analysts plainly believe Rocket Pharmaceuticals is more favorable than Arcus Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rocket Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.90Arcus Biosciences 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.00 Is RCKT or RCUS more profitable? Rocket Pharmaceuticals has a net margin of 0.00% compared to Arcus Biosciences' net margin of -100.81%. Arcus Biosciences' return on equity of -42.86% beat Rocket Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Rocket PharmaceuticalsN/A -54.47% -47.99% Arcus Biosciences -100.81%-42.86%-20.90% Which has more volatility and risk, RCKT or RCUS? Rocket Pharmaceuticals has a beta of 1.09, meaning that its share price is 9% more volatile than the S&P 500. Comparatively, Arcus Biosciences has a beta of 0.89, meaning that its share price is 11% less volatile than the S&P 500. Does the MarketBeat Community favor RCKT or RCUS? Rocket Pharmaceuticals received 189 more outperform votes than Arcus Biosciences when rated by MarketBeat users. Likewise, 72.76% of users gave Rocket Pharmaceuticals an outperform vote while only 65.65% of users gave Arcus Biosciences an outperform vote. CompanyUnderperformOutperformRocket PharmaceuticalsOutperform Votes38272.76% Underperform Votes14327.24% Arcus BiosciencesOutperform Votes19365.65% Underperform Votes10134.35% Do institutionals and insiders hold more shares of RCKT or RCUS? 98.4% of Rocket Pharmaceuticals shares are owned by institutional investors. Comparatively, 92.9% of Arcus Biosciences shares are owned by institutional investors. 28.5% of Rocket Pharmaceuticals shares are owned by insiders. Comparatively, 12.3% of Arcus Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Which has stronger valuation and earnings, RCKT or RCUS? Rocket Pharmaceuticals has higher earnings, but lower revenue than Arcus Biosciences. Rocket Pharmaceuticals is trading at a lower price-to-earnings ratio than Arcus Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRocket PharmaceuticalsN/AN/A-$245.60M-$2.79-6.09Arcus Biosciences$117M12.11-$307M-$3.09-5.02 Does the media prefer RCKT or RCUS? In the previous week, Arcus Biosciences had 1 more articles in the media than Rocket Pharmaceuticals. MarketBeat recorded 4 mentions for Arcus Biosciences and 3 mentions for Rocket Pharmaceuticals. Arcus Biosciences' average media sentiment score of -0.35 beat Rocket Pharmaceuticals' score of -0.49 indicating that Arcus Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rocket Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Arcus Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral SummaryRocket Pharmaceuticals beats Arcus Biosciences on 10 of the 18 factors compared between the two stocks. Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here Get Rocket Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RCKT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RCKT vs. The Competition Export to ExcelMetricRocket PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.55B$7.02B$5.39B$8.53BDividend YieldN/A7.96%5.13%4.14%P/E Ratio-6.099.47113.8115.12Price / SalesN/A381.571,483.2593.03Price / CashN/A47.3339.6434.05Price / Book3.115.324.665.02Net Income-$245.60M$153.56M$119.06M$225.46M7 Day Performance-0.35%0.12%0.79%0.37%1 Month Performance0.12%15.23%5.65%3.57%1 Year Performance-11.61%41.16%36.76%29.42% Rocket Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RCKTRocket Pharmaceuticals4.3151 of 5 stars$16.98+2.0%$51.75+204.8%-10.6%$1.55BN/A-6.09240Upcoming EarningsRCUSArcus Biosciences2.7196 of 5 stars$15.72-1.8%$33.67+114.2%-2.0%$1.44B$247M-5.09500Upcoming EarningsAUPHAurinia Pharmaceuticals2.3482 of 5 stars$7.37+0.1%$10.00+35.7%+2.7%$1.05B$207.11M-21.68300Upcoming EarningsNews CoverageYMABY-mAbs Therapeutics3.2942 of 5 stars$14.70-1.0%$21.14+43.8%+163.2%$655.18M$86.55M-26.25150Upcoming EarningsNews CoveragePositive NewsHRTXHeron Therapeutics3.6412 of 5 stars$1.73-3.9%$6.00+246.8%+183.1%$260.63M$136.36M-5.41300Positive NewsAMRNAmarin0.3795 of 5 stars$0.59-2.8%N/A-16.0%$240.45M$264.78M-7.32360Earnings ReportNews CoverageCYTKCytokinetics4.2656 of 5 stars$50.79-1.0%$83.93+65.2%+47.6%$5.98B$3.13M-9.46250Upcoming EarningsInsider SellingShort Interest ↓NUVLNuvalent3.2685 of 5 stars$89.90-0.4%$112.40+25.0%+66.2%$5.83BN/A-32.3440Insider SellingBPMCBlueprint Medicines2.2147 of 5 stars$88.72-0.6%$118.39+33.4%+51.4%$5.56B$362.80M-25.94640Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageKRYSKrystal Biotech4.639 of 5 stars$173.42-1.2%$196.75+13.5%+47.8%$4.95B$166.23M47.51229Upcoming EarningsOGNOrganon & Co.4.7 of 5 stars$18.91+5.5%$21.33+12.8%+23.2%$4.87B$6.35B4.8610,000Dividend AnnouncementNews Coverage Related Companies and Tools Related Companies RCUS Competitors AUPH Competitors YMAB Competitors HRTX Competitors AMRN Competitors CYTK Competitors NUVL Competitors BPMC Competitors KRYS Competitors OGN Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:RCKT) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredNvidia warning urgentI thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rocket Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rocket Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
